Literature DB >> 28948716

Fibroblast growth factor 22 is a novel modulator of depression through interleukin-1β.

Yu-Hao Xu1, Ming Yu1, Hong Wei1, Shun Yao1, Si-Yuan Chen1, Xiao-Lan Zhu2, Yue-Feng Li1.   

Abstract

BACKGROUND AND AIMS: Emerging evidence shows that fibroblast growth factor 22 (FGF22) plays a critical role in the etiology of depression. However, the molecular mechanisms of FGF22 are not fully comprehended. Here, the effect of FGF22 in depression and its relationship with interleukin-1β (IL-1β) were investigated in clinical, animal, and cell experiments.
METHODS: Serum from depressive patients was collected, and the levels of FGF22 and IL-1β were analyzed by ELISA. The chronic unpredictable mild stress (CUMS) model was established, and primary hippocampal neuronal cells were cultured to examine changes in FGF22 and IL-1β levels in rat hippocampus.
RESULTS: The results revealed a negative correlation between serum FGF22 levels and serum IL-1β levels. The expression of IL-1β in the CUMS rat hippocampus decreased, and the apoptosis of hippocampal cells improved after the injection of lentiviral vector-mediated FGF22 (LV-FGF22). Further tests in primary hippocampal neuronal cells also showed a reduction in IL-1β and the cell apoptosis rate after treatment with FGF22.
CONCLUSION: In conclusion, the results revealed that FGF22 plays a role in alleviating depression, which may be mediated by reduced expression of IL-1β.
© 2017 John Wiley & Sons Ltd.

Entities:  

Keywords:  depression; fibroblast growth factor 22; hippocampus; interleukin-1β

Mesh:

Substances:

Year:  2017        PMID: 28948716      PMCID: PMC6492756          DOI: 10.1111/cns.12760

Source DB:  PubMed          Journal:  CNS Neurosci Ther        ISSN: 1755-5930            Impact factor:   5.243


  31 in total

1.  FGF signaling antagonizes cytokine-mediated repression of Sox9 in SW1353 chondrosarcoma cells.

Authors:  J F Schaefer; M L Millham; B de Crombrugghe; L Buckbinder
Journal:  Osteoarthritis Cartilage       Date:  2003-04       Impact factor: 6.576

2.  Fibroblast growth factor 9 is a novel modulator of negative affect.

Authors:  Elyse L Aurbach; Edny Gula Inui; Cortney A Turner; Megan H Hagenauer; Katherine E Prater; Jun Z Li; Devin Absher; Najmul Shah; Peter Blandino; William E Bunney; Richard M Myers; Jack D Barchas; Alan F Schatzberg; Stanley J Watson; Huda Akil
Journal:  Proc Natl Acad Sci U S A       Date:  2015-09-08       Impact factor: 11.205

3.  The effect of antidepressant medication treatment on serum levels of inflammatory cytokines: a meta-analysis.

Authors:  Jonas Hannestad; Nicole DellaGioia; Michael Bloch
Journal:  Neuropsychopharmacology       Date:  2011-07-27       Impact factor: 7.853

Review 4.  Risk factors for development of depression and psychosis. Glucocorticoid receptors and pituitary implications for treatment with antidepressant and glucocorticoids.

Authors:  Carmine M Pariante
Journal:  Ann N Y Acad Sci       Date:  2009-10       Impact factor: 5.691

5.  Changes of ultrastructure and downregulation of heat shock protein 70 and fibroblast growth factor 2 in gastric mucosa of rats with depressive-like behaviour.

Authors:  Gonglin Hou; Mingming Tang; Linlin Yan; Mingming Wang
Journal:  Acta Neuropsychiatr       Date:  2012-06       Impact factor: 3.403

Review 6.  The fibroblast growth factor family: neuromodulation of affective behavior.

Authors:  Cortney A Turner; Stanley J Watson; Huda Akil
Journal:  Neuron       Date:  2012-10-04       Impact factor: 17.173

7.  The therapeutic use of osmotic minipumps in the severe combined immunodeficiency (SCID) mouse model for rheumatoid arthritis.

Authors:  A Knedla; B Riepl; S Lefèvre; S Kistella; J Grifka; R H Straub; S Gay; J Schölmerich; U Müller-Ladner; E Neumann
Journal:  Ann Rheum Dis       Date:  2008-03-13       Impact factor: 19.103

8.  Deletion of fibroblast growth factor 22 (FGF22) causes a depression-like phenotype in adult mice.

Authors:  Aislinn J Williams; Patricia Yee; Mitchell C Smith; Geoffrey G Murphy; Hisashi Umemori
Journal:  Behav Brain Res       Date:  2016-03-29       Impact factor: 3.332

9.  Treatment with an interleukin-1 receptor antagonist protein prolongs mouse islet allograft survival.

Authors:  J O Sandberg; D L Eizirik; S Sandler; D E Tracey; A Andersson
Journal:  Diabetes       Date:  1993-12       Impact factor: 9.461

10.  Powerful anticonvulsant action of IL-1 receptor antagonist on intracerebral injection and astrocytic overexpression in mice.

Authors:  A Vezzani; D Moneta; M Conti; C Richichi; T Ravizza; A De Luigi; M G De Simoni; G Sperk; S Andell-Jonsson; J Lundkvist; K Iverfeldt; T Bartfai
Journal:  Proc Natl Acad Sci U S A       Date:  2000-10-10       Impact factor: 11.205

View more
  5 in total

1.  Fibroblast growth factor 22 is a novel modulator of depression through interleukin-1β.

Authors:  Yu-Hao Xu; Ming Yu; Hong Wei; Shun Yao; Si-Yuan Chen; Xiao-Lan Zhu; Yue-Feng Li
Journal:  CNS Neurosci Ther       Date:  2017-09-25       Impact factor: 5.243

Review 2.  Selection of the Male or Female Sex in Chronic Unpredictable Mild Stress-Induced Animal Models of Depression.

Authors:  Shuo Jiang; Ling Lin; Lihua Guan; Youming Wu
Journal:  Biomed Res Int       Date:  2022-06-30       Impact factor: 3.246

Review 3.  Roles of Fibroblast Growth Factors and Their Therapeutic Potential in Treatment of Ischemic Stroke.

Authors:  Confidence Dordoe; Keyang Chen; Wenting Huang; Jun Chen; Jian Hu; Xue Wang; Li Lin
Journal:  Front Pharmacol       Date:  2021-04-22       Impact factor: 5.810

4.  Optimization of food deprivation and sucrose preference test in SD rat model undergoing chronic unpredictable mild stress.

Authors:  Li-Wen He; Li Zeng; Na Tian; Yi Li; Tong He; Dong-Mei Tan; Qian Zhang; Yi Tan
Journal:  Animal Model Exp Med       Date:  2020-03-31

Review 5.  Animal models for the study of depressive disorder.

Authors:  Juhyun Song; Young-Kook Kim
Journal:  CNS Neurosci Ther       Date:  2021-03-01       Impact factor: 5.243

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.